Knowledge (XXG)

Athira Pharma

Source 📝

22: 205:(HGF) and its receptor, MET, which are expressed in normal central nervous system function. It aims to regenerate lost connections in the brain, protect brain cells from further damage, and prevent additional neuronal deterioration. ATH-1017 is currently being tested in two clinical studies: ACT-AD and LIFT-AD. 183:
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became Chief Executive Officer.
192:
The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date. Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11, 2019.
375: 201:
The company's lead asset, ATH-1017, is in human trials of Alzheimer's disease as of 2021. ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of
622: 642: 157:
is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as
346:"Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer" 637: 627: 345: 383: 430: 247: 173: 500: 222: 632: 320: 475: 38: 60: 31: 545:"M3 Biotechnology Launches Clinical Trials for Alzheimer's Disease Drug Focused on Restoring Lost Connections in the Brain" 566:"A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease" 449: 202: 162: 158: 573: 248:"ADDF Funding Advances M3 Biotechnology Toward Clinical Trials | Alzheimer's Drug Discovery Foundation" 172:. Funding that supports the company is from both public and private investment groups including the 165:. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. 376:"Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation" 42: 544: 586: 461: 37:
It may require cleanup to comply with Knowledge (XXG)'s content policies, particularly
616: 90: 80: 405: 271: 565: 223:"Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update" 176:, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, 296: 177: 406:"M3 Biotechnology Company Profile: Valuation & Investors | PitchBook" 520: 501:"Dosing Starts in Phase 2/3 Trial of Athira's ATH-1017 for Alzheimer's" 169: 117: 86: 272:"First Trial of Alzheimer's Drug Underway | Science and Enterprise" 476:"Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma" 431:"M3 Biotechnology Announces Name Change to Athira Pharma, Inc" 15: 605: 168:
The company was founded in 2011 and is headquartered in
141: 321:"Entrepreneurship has grown on M3 Biotechnology's CEO" 30:
A major contributor to this article appears to have a
136: 128: 112: 104: 96: 78: 297:"Individual Grants | Life Sciences Discovery Fund" 8: 623:Biotechnology companies of the United States 180:, WRF Capital, and other private investors. 73: 643:Biotechnology companies established in 2011 499:Delgado, Diana Campelo (12 October 2020). 72: 638:2011 establishments in Washington (state) 61:Learn how and when to remove this message 214: 628:American companies established in 2011 582: 571: 457: 447: 350:Athira Pharma - Company Press Releases 174:Alzheimer's Drug Discovery Foundation 7: 369: 367: 374:Soper, Taylor (October 21, 2021). 14: 41:. Please discuss further on the 20: 276:sciencebusiness.technewslit.com 100:Biotechnology, Pharmaceuticals 1: 564:Athira Pharma (2021-08-24). 659: 633:Companies based in Seattle 203:Hepatocyte Growth Factor 581:Cite journal requires 39:neutral point of view 429:Inc, Athira Pharma. 252:www.alzdiscovery.org 386:on October 21, 2021 163:Parkinson's disease 159:Alzheimer's disease 75: 460:has generic name ( 450:cite press release 435:www.prnewswire.com 352:. October 21, 2021 74:Athira Pharma Inc. 325:The Seattle Times 278:. 17 October 2017 152: 151: 71: 70: 63: 34:with its subject. 650: 609: 608: 606:Official website 591: 590: 584: 579: 577: 569: 561: 555: 554: 552: 551: 541: 535: 534: 532: 531: 517: 511: 510: 508: 507: 496: 490: 489: 487: 486: 472: 466: 465: 459: 455: 453: 445: 443: 442: 426: 420: 419: 417: 416: 402: 396: 395: 393: 391: 382:. Archived from 371: 362: 361: 359: 357: 342: 336: 335: 333: 332: 317: 311: 310: 308: 307: 293: 287: 286: 284: 283: 268: 262: 261: 259: 258: 244: 238: 237: 235: 234: 219: 148: 145: 143: 76: 66: 59: 55: 52: 46: 32:close connection 24: 23: 16: 658: 657: 653: 652: 651: 649: 648: 647: 613: 612: 604: 603: 600: 595: 594: 580: 570: 563: 562: 558: 549: 547: 543: 542: 538: 529: 527: 519: 518: 514: 505: 503: 498: 497: 493: 484: 482: 474: 473: 469: 456: 446: 440: 438: 437:(Press release) 428: 427: 423: 414: 412: 404: 403: 399: 389: 387: 373: 372: 365: 355: 353: 344: 343: 339: 330: 328: 319: 318: 314: 305: 303: 295: 294: 290: 281: 279: 270: 269: 265: 256: 254: 246: 245: 241: 232: 230: 221: 220: 216: 211: 199: 197:Core technology 190: 140: 124: 120: 83: 67: 56: 50: 47: 36: 25: 21: 12: 11: 5: 656: 654: 646: 645: 640: 635: 630: 625: 615: 614: 611: 610: 599: 598:External links 596: 593: 592: 583:|journal= 556: 536: 521:"Our Approach" 512: 491: 467: 421: 397: 363: 337: 312: 288: 263: 239: 213: 212: 210: 207: 198: 195: 189: 186: 150: 149: 138: 134: 133: 130: 126: 125: 122: 116: 114: 110: 109: 106: 102: 101: 98: 94: 93: 84: 79: 69: 68: 28: 26: 19: 13: 10: 9: 6: 4: 3: 2: 655: 644: 641: 639: 636: 634: 631: 629: 626: 624: 621: 620: 618: 607: 602: 601: 597: 588: 575: 567: 560: 557: 546: 540: 537: 526: 525:Athira Pharma 522: 516: 513: 502: 495: 492: 481: 480:FierceBiotech 477: 471: 468: 463: 451: 436: 432: 425: 422: 411: 410:pitchbook.com 407: 401: 398: 385: 381: 377: 370: 368: 364: 351: 347: 341: 338: 326: 322: 316: 313: 302: 301:www.lsdfa.org 298: 292: 289: 277: 273: 267: 264: 253: 249: 243: 240: 228: 227:Athira Pharma 224: 218: 215: 208: 206: 204: 196: 194: 187: 185: 181: 179: 175: 171: 166: 164: 160: 156: 155:Athira Pharma 147: 139: 135: 131: 127: 123:United States 119: 115: 111: 107: 103: 99: 95: 92: 88: 85: 82: 77: 65: 62: 54: 44: 40: 35: 33: 27: 18: 17: 574:cite journal 559: 548:. Retrieved 539: 528:. Retrieved 524: 515: 504:. Retrieved 494: 483:. Retrieved 479: 470: 439:. Retrieved 434: 424: 413:. Retrieved 409: 400: 388:. Retrieved 384:the original 379: 354:. Retrieved 349: 340: 329:. Retrieved 327:. 2017-04-30 324: 315: 304:. Retrieved 300: 291: 280:. Retrieved 275: 266: 255:. Retrieved 251: 242: 231:. Retrieved 229:. 2021-08-16 226: 217: 200: 191: 182: 167: 154: 153: 113:Headquarters 57: 48: 29: 458:|last= 617:Categories 550:2018-10-15 530:2021-10-20 506:2021-08-30 485:2021-10-20 441:2019-04-15 415:2018-10-15 331:2018-07-31 306:2018-07-31 282:2018-10-15 257:2018-10-15 233:2021-10-20 209:References 178:The W Fund 51:March 2019 81:Traded as 43:talk page 390:July 10, 380:GeekWire 356:July 10, 132:ATH-1017 129:Products 97:Industry 188:History 170:Seattle 144:.athira 137:Website 118:Seattle 105:Founded 89::  87:Nasdaq 587:help 462:help 392:2022 358:2022 161:and 146:.com 108:2011 91:ATHA 142:www 619:: 578:: 576:}} 572:{{ 523:. 478:. 454:: 452:}} 448:{{ 433:. 408:. 378:. 366:^ 348:. 323:. 299:. 274:. 250:. 225:. 121:, 589:) 585:( 568:. 553:. 533:. 509:. 488:. 464:) 444:. 418:. 394:. 360:. 334:. 309:. 285:. 260:. 236:. 64:) 58:( 53:) 49:( 45:.

Index

close connection
neutral point of view
talk page
Learn how and when to remove this message
Traded as
Nasdaq
ATHA
Seattle
www.athira.com
Alzheimer's disease
Parkinson's disease
Seattle
Alzheimer's Drug Discovery Foundation
The W Fund
Hepatocyte Growth Factor
"Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update"
"ADDF Funding Advances M3 Biotechnology Toward Clinical Trials | Alzheimer's Drug Discovery Foundation"
"First Trial of Alzheimer's Drug Underway | Science and Enterprise"
"Individual Grants | Life Sciences Discovery Fund"
"Entrepreneurship has grown on M3 Biotechnology's CEO"
"Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer"


"Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation"
the original
"M3 Biotechnology Company Profile: Valuation & Investors | PitchBook"
"M3 Biotechnology Announces Name Change to Athira Pharma, Inc"
cite press release
help
"Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma"

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.